NeOnc Technologies Holdings (NTHI) investor relations material

Executive summary

• Q3 net loss was $4.44M; nine-month net loss was $27.50M, down from $46.62M YoY. Cash was $6.17M at September 30, with substantial doubt about the ability to continue as a going concern.

• NEO100 met its Phase 2a primary endpoint; NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2. Neither program has product sales revenue.

Financial highlights

• Q3 net loss was $4.44M versus $8.6M in Q3 2025; operating expenses were $5.83M versus $6.93M.

• Q3 net loss attributable to common stockholders was $7.27M, or $0.28 per share, including a $2.66M deemed dividend on Series A redemption and a $0.18M warrant down-round adjustment.

• Nine-month operating expenses were $26.96M versus $44.54M; net loss was $27.50M versus $46.62M, and net loss attributable to common stockholders was $30.33M versus $46.62M.

• Nine-month cash used in operations was $16.85M and financing provided $22.95M, increasing cash by $6.11M.

• Cash and cash equivalents were $6.17M at September 30, up from $2.0M at June 30; nine-month stock-based compensation was $8.65M.

Outlook and guidance

• NEO100 Phase 2a results support an intended accelerated-approval strategy for recurrent IDH-mutant grade 4 astrocytoma; FDA feedback meetings on clinical strategy and CMC were requested in October.

• NEO212 Phase 1 dose escalation is complete; a randomized Phase 2 design is planned, with an FDA End-of-Phase 1 meeting scheduled for November 23, 2026.

• R&D costs are expected to rise significantly as trials advance; development costs through commercialization cannot yet be reliably estimated.

• Operations are expected to be funded through cash, the HCWG credit facility and ATM sales, but available resources are insufficient for 12 months and additional capital is required.

• NEO100 and NEO212 clinical data were scheduled for presentation at the Society for Neuro-Oncology Annual Meeting on November 13, 2026.